Oral Biologics & Biosimilar Drugs Market Report 2026

Oral Biologics & Biosimilar Drugs Market Overview

• Oral Biologics & Biosimilar Drugs market size has reached to $8.6 billion in 2025 • Expected to grow to $17.17 billion in 2030 at a compound annual growth rate (CAGR) of 13.3% • Growth Driver: Rising Prevalence Of Chronic Diseases Driving Growth In The Oral Biologics And Biosimilar Drugs Market • Market Trend: Advancements In Oral Biologics For Obesity Management • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Oral Biologics & Biosimilar Drugs Market?

A biosimilar refers to a medication that closely resembles a biological medication in both structure and function. A biological drug, however, is a treatment created using a biological system, such as yeast, bacteria, or animal cells. A biological product is considered 'biosimilar' if it is extremely similar to and bears no discernible clinical differences from an FDA-approved reference product already in use. The main therapy types are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that stop interleukins from working. Interleukins are a family of cytokines produced by lymphocytes, monocytes, macrophages, and a few other cells. They play an important role in immune system regulation. The various diseases treated include asthma, Crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others, by vaccines, proteins and peptides, monoclonal antibodies, and others. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Oral Biologics & Biosimilar Drugs Market Growth Forecast?

The oral biologics & biosimilar drugs market size is expected to see rapid growth in the next few years. It will grow to $17.17 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to development of next-generation oral biologics, expansion of biosimilar pipeline, increasing adoption of combination therapies, growing digital health platforms for patient monitoring, rising regulatory support for biosimilar approvals. Major trends in the forecast period include rising adoption of oral biologics and biosimilar drugs, increasing focus on chronic disease management using biologics, expansion of hospital and retail pharmacy distribution channels, growth in patient awareness and acceptance of biosimilars, development of targeted therapies for autoimmune and inflammatory diseases.

What Is The Driver Of The Oral Biologics & Biosimilar Drugs Market?

The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. For instance, in May 2023 According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the oral biologics & biosimilar drugs industry growth.

Key Players In The Global Oral Biologics & Biosimilar Drugs Market

Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

Global Oral Biologics & Biosimilar Drugs Market Trends and Insights

Major companies operating in the oral biologics and biosimilar markets are focusing on innovative products, such as incretin triagonists, to enhance patient outcomes, improve drug efficacy, and provide alternatives to injectable therapies. Incretin triagonists are drugs that simultaneously activate three hormone receptors GLP-1, GIP, and glucagon, which help regulate blood sugar, appetite, and metabolism. For instance, in October 2024, Rani Therapeutics Holdings Inc., a US-based biotechnology company, released new preclinical pharmacokinetic data supporting the transenteric delivery of a GLP-1 incretin triagonist. Their RaniPill, an oral capsule designed for delivering biologics traditionally requiring injections, successfully delivered an incretin triagonist targeting GLP-1, GIP, and glucagon receptors key targets in obesity treatment. The RaniPill demonstrated comparable effectiveness to subcutaneous injections, offering a needle-free alternative with high bioavailability and flexible dosing, establishing it as a promising solution for obesity drug candidates.

What Are Latest Mergers And Acquisitions In The Oral Biologics & Biosimilar Drugs Market?

In August 2023, Oramed Pharmaceuticals Inc., a US-based pharmaceutical company, formed a joint venture with Hefei Tianhui Incubator of Technologies Co., Ltd. (HTIT) to develop and commercialize oral drug products. The collaboration aims to advance the development of innovative oral formulations, improve patient adherence, and expand access to orally administered therapies, enhancing treatment options while fostering growth and innovation in the oral drug delivery sector. Hefei Tianhui Incubator of Technologies Co., Ltd. (HTIT) is a China-based healthcare technology and innovation company focused on developing next-generation pharmaceutical solutions.

What Defines the Oral Biologics & Biosimilar Drugs Market?

The oral biologics and biosimilar market consist of sales of therapeutic proteins, cystic fibrosis, somatic cells, and allergenics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Biologics & Biosimilar Drugs Market Report 2026?

The oral biologics & biosimilar drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics & biosimilar drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.